Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Cancer symbols : Gnpx save search
Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer
Published: 2024-04-03 (Crawled : 12:30) - prnewswire.com
GNPX | $2.2194 -2.31% 38K
|
Health Technology
|
| O: 1.76%
H: 13.15%
C: 7.61%
reqorsa lung cancer treat cell trial therapy study
Genprex Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa® Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer
Published: 2024-02-05 (Crawled : 12:30) - prnewswire.com
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: -0.17%
H: 0.09%
C: -2.76%
GNPX | $2.2194 -2.31% 38K
|
Health Technology
|
| O: 33.84%
H: 1.01%
C: -15.3%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.76%
H: 0.77%
C: 0.0%
reqorsa first lung cancer treat cell expansion therapy study
Genprex to Present Data on the Use of REQORSA® for the Treatment of Lung Cancers at 2023 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Published: 2023-10-04 (Crawled : 16:00) - prnewswire.com
GNPX | $2.2194 -2.31% 38K
|
Health Technology
|
| O: 1.42%
H: 9.24%
C: 3.64%
reqorsa lung conference cancer international treatment therapeutics molecular
Genprex Granted FDA Orphan Drug Designation (ODD) for REQORSA® Immunogene Therapy for the Treatment of Small Cell Lung Cancer
Published: 2023-08-10 (Crawled : 13:00) - biospace.com/
GNPX | $2.2194 -2.31% 38K
|
Health Technology
|
| O: 6.25%
H: 1.75%
C: -5.57%
reqorsa fda lung drug granted cancer cell treatment designation therapy
Gene Therapy Company Genprex, Inc. (NASDAQ: GNPX) Receives Fast Track Designation From The FDA For Its Small Cell Lung Cancer Drug Candidate
Published: 2023-07-11 (Crawled : 14:00) - biospace.com/
GNPX | $2.2194 -2.31% 38K
|
Health Technology
|
| O: 1.25%
H: 3.41%
C: -1.43%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.28%
H: 0.25%
C: -0.23%
fda lung drug candidate cancer cell designation therapy fast track designation
Genprex Receives U.S. FDA Fast Track Designation for REQORSA® Immunogene Therapy in Combination with Tecentriq® for the Treatment of Small Cell Lung Cancer
Published: 2023-06-28 (Crawled : 14:00) - biospace.com/
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: -2.36%
GNPX | $2.2194 -2.31% 38K
|
Health Technology
|
| O: 14.85%
H: 1.18%
C: -7.27%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.29%
H: 0.13%
C: -0.7%
reqorsa fda lung cancer cell treatment designation therapy fast track designation
Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Expansion Portion of Acclaim-1 Clinical Trial of REQORSA® in Combination with Tagrisso® in Advanced Non-Small Cell Lung Cancer
Published: 2023-05-30 (Crawled : 13:00) - biospace.com/
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: -0.34%
H: 0.21%
C: -2.03%
GNPX | $2.2194 -2.31% 38K
|
Health Technology
|
| O: 1.12%
H: 2.16%
C: -10.76%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.44%
H: 0.03%
C: -1.94%
reqorsa lung approval review cancer cell expansion trial
Genprex Publishes Positive Clinical Data from Phase 1 Portion of Acclaim-1 Clinical Trial Evaluating REQORSA® Immunogene Therapy in Non-Small Cell Lung Cancer at the 2023 ASCO Annual Meeting
Published: 2023-05-25 (Crawled : 21:00) - prnewswire.com
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: -0.47%
H: 0.0%
C: -0.02%
GNPX | $2.2194 -2.31% 38K
|
Health Technology
|
| O: 3.65%
H: 7.04%
C: 1.02%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 1.06%
H: 0.48%
C: -0.04%
reqorsa lung asco positive cancer cell meeting trial therapy
Genprex Collaborators Report Positive Preclinical Data With NPRL2 Gene Therapy Utilizing Non-Viral ONCOPREX® Nanoparticle Delivery System in Non-Small Cell Lung Cancer at the 2023 AACR Annual Meeting
Published: 2023-04-19 (Crawled : 13:20) - prnewswire.com
GNPX | $2.2194 -2.31% 38K
|
Health Technology
|
| O: 15.79%
H: 0.0%
C: -10.0%
oncoprex lung report positive cancer cell system preclinical meeting therapy
Genprex Receives Safety Review Committee Approval to Proceed to Final Cohort in Acclaim-1 Phase 1 Dose Escalation Trial of REQORSA® in Combination with Tagrisso® in Advanced Non-Small Cell Lung Cancer
Published: 2022-12-14 (Crawled : 19:00) - biospace.com/
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: -1.61%
H: 1.82%
C: 1.82%
GNPX | $2.2194 -2.31% 38K
|
Health Technology
|
| O: 2.34%
H: 5.98%
C: -0.85%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.76%
H: 1.04%
C: 0.47%
reqorsa lung trial approval review cancer
Genprex Announces Safety Review Committee Approves Dose Escalation in Acclaim-1 Phase 1/2 Trial of REQORSA™ in Combination with Tagrisso® in Non-Small Cell Lung Cancer
Published: 2022-08-15 (Crawled : 12:20) - biospace.com/
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 3.35%
H: 0.0%
C: -0.09%
GNPX | $2.2194 -2.31% 38K
|
Health Technology
|
| O: 7.91%
H: 13.09%
C: 9.42%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.92%
H: 0.22%
C: -0.65%
tagrisso lung trial review cancer phase 1
Genprex's Chief Medical Officer to Be Featured as an Expert Panelist at the 33rd Annual Cancer Progress Conference
Published: 2022-05-09 (Crawled : 12:20) - biospace.com/
GNPX | $2.2194 -2.31% 38K
|
Health Technology
|
| O: -7.41%
H: 1.99%
C: -8.0%
conference cancer
Genprex Announces the Opening for Enrollment of its Phase 1/2 Acclaim-2 Clinical Trial of REQORSA™ Immunogene Therapy in Combination With Keytruda® to Treat Non-Small Cell Lung Cancer
Published: 2022-03-31 (Crawled : 12:00) - biospace.com/
GNPX | $2.2194 -2.31% 38K
|
Health Technology
|
| O: 1.96%
H: 0.0%
C: -3.62%
keytruda trial therapy cancer enroll phase 1
Genprex Announces First Patient Dosed in Phase 1/2 Acclaim-1 Clinical Trial of REQORSA™ Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer
Published: 2022-03-02 (Crawled : 14:00) - biospace.com/
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 0.37%
H: 2.02%
C: 2.02%
GNPX | $2.2194 -2.31% 38K
|
Health Technology
|
| O: 3.95%
H: 5.06%
C: -7.17%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.62%
H: 0.0%
C: 0.0%
tagrisso gene therapy trial cel lung cancer phase 1 therapy cancer
Preclinical Data Show Potential for Use of Genprex’s ONCOPREX® Nanoparticle Delivery System in Treating Colon Cancer
Published: 2022-01-27 (Crawled : 18:00) - biospace.com/
GNPX | $2.2194 -2.31% 38K
|
Health Technology
|
| O: 0.52%
H: 20.51%
C: -5.13%
oncoprex liver system preclinical potential cancer pre-clinical
Genprex to Participate in January 2022 Investor and Healthcare Conferences to Highlight Company’s Gene Therapies in Cancer and Diabetes
Published: 2022-01-05 (Crawled : 10:00) - biospace.com/
GNPX | $2.2194 -2.31% 38K
|
Health Technology
|
| O: -13.14%
H: 0.0%
C: 0.0%
health thc conference diabetes gene therapies cancer gene therapy therapy
Genprex Expands Gene Therapy Oncology Pipeline to Include Small Cell Lung Cancer
Published: 2022-01-04 (Crawled : 16:00) - biospace.com/
GNPX | $2.2194 -2.31% 38K
|
Health Technology
|
| O: 103.92%
H: 0.0%
C: 0.0%
gene therapy cel lung cancer therapy cancer
Genprex Receives U.S. FDA Fast Track Designation for REQORSA™ Immunogene Therapy in Combination With Keytruda® for the Treatment of Non-Small Cell Lung Cancer
Published: 2022-01-03 (Crawled : 15:00) - biospace.com/
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 2.49%
H: 1.06%
C: -2.49%
GNPX | $2.2194 -2.31% 38K
|
Health Technology
|
| O: 16.79%
H: 0.0%
C: 0.0%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.03%
H: 0.17%
C: 0.07%
keytruda fast track designation treatment fda fast track gene therapy cel fda fast track lung cancer therapy cancer designation
Genprex Announces Initiation of its Phase 1/2 Acclaim-1 Clinical Trial for REQORSA™ Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer Following FDA Review
Published: 2021-06-23 (Crawled : 18:00) - biospace.com/
GNPX | $2.2194 -2.31% 38K
|
Health Technology
|
| O: 5.45%
H: 11.78%
C: 6.9%
fda lung cancer phase 1 gene therapy therapy cancer trial
Genprex Announces Centralized Institutional Review Board Approval for Acclaim-1 Clinical Trial in Non-Small Cell Lung Cancer
Published: 2021-05-05 (Crawled : 17:00) - biospace.com/
GNPX | $2.2194 -2.31% 38K
|
Health Technology
|
| O: 0.54%
H: 3.11%
C: -1.89%
lung cancer cancer trial approval
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.